Citius Pharmaceuticals (NASDAQ:CTXR) Trading Down 11.2% – What’s Next?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) shares dropped 11.2% during trading on Monday . The stock traded as low as $0.81 and last traded at $0.86. Approximately 245,588 shares changed hands during mid-day trading, an increase of 36% from the average daily volume of 180,373 shares. The stock had previously closed at $0.97.

Wall Street Analyst Weigh In

Separately, D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Citius Pharmaceuticals in a research note on Tuesday, February 18th.

Citius Pharmaceuticals Stock Performance

The firm has a 50 day moving average of $1.49 and a 200-day moving average of $3.96.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its earnings results on Friday, February 14th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($0.05). On average, equities analysts forecast that Citius Pharmaceuticals, Inc. will post -4.5 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Citius Pharmaceuticals

Several hedge funds have recently bought and sold shares of CTXR. Geode Capital Management LLC lifted its holdings in shares of Citius Pharmaceuticals by 14.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock worth $941,000 after buying an additional 232,656 shares during the period. Chelsea Counsel Co. grew its holdings in Citius Pharmaceuticals by 9.8% during the 3rd quarter. Chelsea Counsel Co. now owns 281,300 shares of the company’s stock worth $141,000 after acquiring an additional 25,000 shares in the last quarter. Virtu Financial LLC purchased a new position in Citius Pharmaceuticals during the 3rd quarter valued at about $50,000. XTX Topco Ltd bought a new stake in shares of Citius Pharmaceuticals in the 3rd quarter valued at about $47,000. Finally, IFP Advisors Inc boosted its stake in shares of Citius Pharmaceuticals by 21.2% during the fourth quarter. IFP Advisors Inc now owns 40,416 shares of the company’s stock valued at $162,000 after purchasing an additional 7,083 shares in the last quarter. Institutional investors own 16.88% of the company’s stock.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.